Teva Drops Most in a Month as Amgen Patent Litigation Resolved - Bloomberg

Teva Pharmaceutical Industries Ltd. declined the most in almost a month after a U.S. district court found the world’s largest generic drugmaker infringed Amgen Inc. patents relating to human G-CSF. The shares slid 2.6 percent, the most since June 19, to 165 shekels at 10:12 a.m. in Tel Aviv. The court issued a permanent injunction preventing Teva from selling Neutroval in...